Efficacy of High-Intensity Local Treatment for Metastatic Urothelial Carcinoma of the Bladder: A Propensity Score-Weighted Analysis From the National Cancer Data Base [Urologic Oncology]
Conclusion
We report an OS benefit for individuals with mUCB treated with high-intensity versus conservative LT. Although the findings are subject to the usual biases related to the observational study design, these preliminary data warrant further consideration in randomized controlled trials, particularly given the poor prognosis associated with mUCB. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - October 4, 2016 Category: Cancer & Oncology Authors: Seisen, Sun, Leow, Preston, Cole, Gelpi-Hammerschmidt, Hanna, Meyer, Kibel, Lipsitz, Nguyen, Bellmunt, Choueiri, Trinh Tags: Combined Modality Therapy Urologic Oncology Source Type: research
HER2 Gene Amplification Testing by Fluorescent In Situ Hybridization (FISH): Comparison of the ASCO-College of American Pathologists Guidelines With FISH Scores Used for Enrollment in Breast Cancer International Research Group Clinical Trials [Breast Cancer]
Conclusion
Our findings support the original categorizations of HER2 by FISH status in BCIRG/Translational Research in Oncology trials. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - October 4, 2016 Category: Cancer & Oncology Authors: Press, Sauter, Buyse, Fourmanoir, Quinaux, Tsao-Wei, Eiermann, Robert, Pienkowski, Crown, Martin, Valero, Mackey, Bee, Ma, Villalobos, Campeau, Mirlacher, Lindsay, Slamon Tags: Diagnosis & Staging, Combined Modality, Clinical Trials, Prognostic Studies, ASCO Guidelines, Breast Cancer, Cancer Biomarkers, Growth Factors & Receptor, Oncogenes Source Type: research
T-DM1 Activity in Metastatic Human Epidermal Growth Factor Receptor 2-Positive Breast Cancers That Received Prior Therapy With Trastuzumab and Pertuzumab [Breast Cancer]
Conclusion
Tumor response rates were lower than in prior reports of trastuzumab-resistant, HER2-positive MBC, but one third of patients received therapy with T-DM1 for ≥ 6 months, which suggests a clinically relevant benefit in patients who received prior pertuzumab. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - October 4, 2016 Category: Cancer & Oncology Authors: Dzimitrowicz, Berger, Vargo, Hood, Abdelghany, Raghavendra, Tripathy, Valero, Hatzis, Pusztai, Murthy Tags: Chemotherapy Breast Cancer Source Type: research
Change in Pattern of HER2 Fluorescent in Situ Hybridization (FISH) Results in Breast Cancers Submitted for FISH Testing: Experience of a Reference Laboratory Using US Food and Drug Administration Criteria and American Society of Clinical Oncology and College of American Pathologists Guidelines [Rapid Communication]
Conclusion
In a reference laboratory cohort that was highly enriched for IHC 2+ patient samples, AC2013 guidelines led to a larger number of FISH-equivocal patients. Approximately one half of these FISH-equivocal patients (7.4% overall) became HER2-positive upon alternative FISH probe testing. However, these patients would not have participated in the pivotal HDT trials. Clinical utility data on HDT benefit in these patients and other special subsets are needed. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - October 4, 2016 Category: Cancer & Oncology Authors: Shah, Wiktor, Meyer, Tenner, Ballman, Green, Sukov, Ketterling, Perez, Jenkins Tags: Diagnosis & Staging, Combined Modality, Prognostic Studies, ASCO Guidelines, Rapid Communications Source Type: research
Prostate-Specific Antigen Screening: Time to Change the Dominant Forces on the Pendulum [COMMENTS AND CONTROVERSIES]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - October 4, 2016 Category: Cancer & Oncology Authors: Shoag, Schlegel, Hu Tags: Non-ASCO Guidelines, Diagnosis & Staging COMMENTS AND CONTROVERSIES Source Type: research
Definitive Management of Primary Bladder Tumors in the Context of Metastatic Disease: Who, How, When, and Why? [ONCOLOGY GRAND ROUNDS]
The Oncology Grand Rounds series is designed to place original reports published in the Journal into clinical context. A case presentation is followed by a description of diagnostic and management challenges, a review of the relevant literature, and a summary of the authors’ suggested management approaches. The goal of this series is to help readers better understand how to apply the results of key studies, including those published in Journal of Clinical Oncology, to patients seen in their own clinical practice.
A 70-year-old man with urothelial cancer of the bladder (UBC) metastatic to the pelvic and retroperitonea...
Source: Journal of Clinical Oncology - October 4, 2016 Category: Cancer & Oncology Authors: Galsky, Domingo-Domenech, Sfakianos, Ferket Tags: Oncology Grand Rounds Source Type: research
When Can a Salvage Therapy (T-DM1) Take the Lead? [EDITORIALS]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - October 4, 2016 Category: Cancer & Oncology Authors: Mahtani, Vogel Tags: Chemotherapy EDITORIALS Source Type: research
Let's Not Throw the Baby out With the Bathwater in Prostate Cancer Screening [EDITORIALS]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - October 4, 2016 Category: Cancer & Oncology Authors: Penson, Resnick Tags: Diagnosis & Staging EDITORIALS Source Type: research
Advertising [ONCOLOGY CAREER CENTER]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - October 4, 2016 Category: Cancer & Oncology Tags: ONCOLOGY CAREER CENTER Source Type: research
Targeted Therapies in Older Adults With Breast Cancer: What Do We Know? [CORRESPONDENCE]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - September 20, 2016 Category: Cancer & Oncology Authors: Strulov Shachar, Hurria, Muss Tags: CORRESPONDENCE Source Type: research
Reply to K. Lin et al [CORRESPONDENCE]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - September 20, 2016 Category: Cancer & Oncology Authors: Smith Tags: CORRESPONDENCE Source Type: research
Dangers of Excluding Margin Status From a Ductal Carcinoma In Situ Prognostic Score [CORRESPONDENCE]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - September 20, 2016 Category: Cancer & Oncology Authors: Lin, Lagios, Silverstein Tags: CORRESPONDENCE Source Type: research
Reply to P. de Boissieu et al [CORRESPONDENCE]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - September 20, 2016 Category: Cancer & Oncology Authors: Low, Bovbjerg, Bartlett Tags: CORRESPONDENCE Source Type: research
Impact of Depression in Patients Undergoing Hyperthermic Intraperitoneal Chemotherapy With Cytoreductive Surgery [CORRESPONDENCE]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - September 20, 2016 Category: Cancer & Oncology Authors: de Boissieu, Crespel, Duminil, de Mestier Tags: CORRESPONDENCE Source Type: research
